Back

Histone deacetylase inhibition mitigates cognitive deficits and astrocyte dysfunction induced by Ab oligomers

Morgado, J.; Diniz, L. P.; Araujo, A. P. B.; Antonio, L. M. d. S.; Araujo, H. P. M.; Pinheiro, P. d. S. M.; Sagrillo, F. S.; Cesar, G. V.; Ferreira, S. T.; Figueiredo, C. P.; Fraga, C. A. M.; GOMES, F. C. A.

2023-10-30 neuroscience
10.1101/2023.10.25.564038 bioRxiv
Show abstract

Inhibitors of histone deacetylases (iHDACs) are promising drugs for neurodegenerative diseases. We have evaluated the therapeutic potential of the new iHDAC6 LASSBio-1911 in A{beta} oligomer (A{beta}O) toxicity models and astrocytes, key players in neuroinflammation and Alzheimers disease (AD). Astrocyte phenotype and synapse density were evaluated by flow cytometry, Western blotting, immunofluorescence and qPCR, in vitro and in mice. Cognitive function was evaluated by behavioural assays using a mouse model of intracerebroventricular infusion of A{beta}O. LASSBio-1911 modulates reactivity and synaptogenic potential of cultured astrocytes and improves synaptic markers in cultured neurons and in mice. It prevents A{beta}O-triggered astrocytic reactivity in mice and enhances the neuroprotective potential of astrocytes. LASSBio-1911 improves behavioural performance and rescues synaptic and memory function in A{beta}O-infused mice. These results contribute to unveiling the mechanisms underlying astrocyte role in AD and provide the rationale for using astrocytes as targets to new drugs for AD.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.